Cover Image
市場調查報告書

EpiCast Report:全身性硬化症(硬皮症)- 到2024年前的流行病學預測

EpiCast Report: Systemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2024

出版商 GlobalData 商品編碼 349805
出版日期 內容資訊 英文 68 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:全身性硬化症(硬皮症)- 到2024年前的流行病學預測 EpiCast Report: Systemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2024
出版日期: 2015年12月09日 內容資訊: 英文 68 Pages
簡介

全球主要7國(美國,法國,德國,義大利,西班牙,英國,日本)確診全身性硬化症(硬皮症)的患者數 (18歲以上) ,預測將從2014年的131,129人增加到2024年的141,499人。

本報告提供全球主要7個國家的全身性硬化症(硬皮症)調查分析,提供您疾病背景,危險因素和合併症,全球趨勢,流行病學預測等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 疾病的背景
  • 危險因素和合併症
  • 全球趨勢
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法
  • 全身性硬化症(硬皮症)的流行病學預測
    • 確診的患者數
    • 確診的患者數 (各年齡)
    • 確診的患者數 (性別)
    • 確診的患者數 (年齡標準化) 、等
  • 議論
    • 流行病學預測相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表

目錄
Product Code: GDHCER109-15

Systemic sclerosis (SSc) is an autoimmune disease of the connective tissue, and is characterized by excessive fibrosis, vascular alterations, and the proliferation of antibodies against numerous cellular antigens. SSc mainly affects those ages 40-50 years, and occurs predominantly in women, with a female-to-male sex ratio of 4:1. There are two main forms of the disease: limited and diffuse cutaneous scleroderma (lSSc and dSSc, respectively). lSSc primarily affects the hands, arms, and face, whereas dSSc affects a vast area of the skin and involves one or more internal organs. Raynaud's phenomenon (RP) develops in the majority of both forms of SSc. The primary cause of death in both lSSC and dSSc is involvement of the lungs.

GlobalData epidemiologists forecast that the diagnosed prevalent cases of SSc for ages 18 years and older will increase from 131,129 cases in 2014 to 141,499 cases in 2024. GlobalData epidemiologists forecast that in 2024, the US will have the highest number of diagnosed prevalent cases of SSc, with 95,992 cases, accounting for 68% of cases in the 7MM. In the 7MM in 2014, the group age 50-59 years had the highest proportion of diagnosed prevalent cases of SSc at 25.51%. In 2014, the diagnosed prevalent cases of SSc in the 7MM were lower in men compared with women with 15.36% diagnosed prevalent cases in men and 84.64% diagnosed prevalent cases in women. Of all the diagnosed prevalent cases of SSc in the 7MM in 2014, more had experienced RP (126,151 cases) than a DU (67,099 cases). In each of the 7MM, approximately 95% of the diagnosed prevalent SSc cases had experienced RP. In all markets other than France, Germany, and Italy, 70.50% of the diagnosed prevalent cases of SSc were lSSc. In the 7MM in 2014, 18,395 of the diagnosed prevalent cases of dSSc had ILD, and 6,679 of the diagnosed prevalent cases of dSSc had kidney disease.

GlobalData epidemiologists utilized comprehensive, country-specific data from registries and peer-reviewed journal articles to arrive at a meaningful, in-depth analysis and forecast for the diagnosed prevalent cases of SSc. In this analysis, GlobalData epidemiologists provide detailed, clinically relevant segmentations for the diagnosed prevalent cases of SSc. Finally, the same forecast methodology was used across the 7MM, thereby allowing for meaningful global comparisons of the diagnosed prevalent cases of SSc across these markets.

Scope

  • The Systemic Sclerosis (SSc) EpiCast Report provides an overview of the risk factors and global trends of SSc in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiology forecast of SSc diagnosed prevalent cases in these markets, segmented by age, sex, presence of Raynaud's phenomenon (RP), presence of digital ulcers (DUs), limited systemic sclerosis (ISSc), and diffuse systemic sclerosis (dSSc). The diagnosed prevalent cases of dSSc are further segmented into cases with pulmonary fibrosis (PF)/interstitial lung disease (ILD) and kidney disease.
  • The SSc epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The SSc EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global SSc market.
  • Quantify patient populations in the global SSc market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for SSc therapeutics in each of the markets covered.
  • Identify the percentage of SSc diagnosed prevalent cases by disease type.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast for SSc (2014-2024)
    • 3.5.1. Diagnosed Prevalent Cases of SSc
    • 3.5.2. Age-Specific Diagnosed Prevalent Cases of SSc
    • 3.5.3. Sex-Specific Diagnosed Prevalent Cases of SSc
    • 3.5.4. Age-Standardized Prevalence of SSc
    • 3.5.5. Diagnosed Prevalent Cases of SSc with RP and SSc with DU
    • 3.5.6. SSc Segmented into lSSc and dSSc
    • 3.5.7. Sex-Specific Diagnosed Prevalent Cases of lSSc
    • 3.5.8. Sex-Specific Diagnosed Prevalent Cases of dSSc
    • 3.5.9. Diagnosed Prevalent Cases of dSSc with ILD and Cases with Kidney Disease
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for SSc
  • Table 2: 7MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Prevalent Cases of SSc
  • Table 3: 7MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Prevalent Cases of SSc with RP
  • Table 4: 7MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Prevalent Cases of SSc with DU
  • Table 5: 7MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Prevalent Cases of SSc, Segmented by lSSc and dSSc
  • Table 6: 7MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Prevalent Cases of dSSc with ILD
  • Table 7: 7MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Prevalent Cases of dSSc with Kidney Disease
  • Table 8: 7MM, Diagnosed Prevalent Cases of SSc, Both Sexes, Age ≥18 Years, Select Years, 2014-2024
  • Table 9: 7MM, Age-Specific Diagnosed Prevalent Cases of SSc, Both Sexes, N (Row%), 2014
  • Table 10: 7MM, Sex-Specific Diagnosed Prevalent Cases of SSc, Age ≥18 Years, N (Row %), 2014
  • Table 11: 7MM, Diagnosed Prevalent Cases of SSc with RP, and SSc with DU, Both Sexes, Age ≥18 Years, N (% of Diagnosed Prevalent SSc Cases), 2014
  • Table 12: 7MM, Sex-Specific Diagnosed Prevalent Cases of lSSc, Age ≥18 Years, N (Row %), 2014
  • Table 13: 7MM, Sex-Specific Diagnosed Prevalent Cases of dSSc, Ages ≥18 Years, N (Row %), 2014
  • Table 14: 7MM, Diagnosed Prevalent Cases of dSSc with ILD and dSSc with Kidney Disease, Both Sexes, Age ≥15 Years, N (% of Diagnosed Prevalent dSSc Cases), 2014

List of Figures

  • Figure 1: Case Flow Map of the Diagnosed Prevalent Cases of SSc
  • Figure 2: 7MM, Diagnosed Prevalent Cases of SSc, Both Sexes, Age ≥18 Years, Selected Years, 2014-2024
  • Figure 3: 7MM, Age-Specific Diagnosed Prevalent Cases of SSc, Both Sexes, 2014
  • Figure 4: 7MM, Sex-Specific Diagnosed Prevalent Cases of SSc, Age ≥18 Years, 2014
  • Figure 5: 7MM, Age-Standardized Diagnosed Prevalence of SSc, 2014
  • Figure 6: 7MM, Diagnosed Prevalent Cases of SSc with RP and SSc with DU, Both Sexes, Age ≥18 Years, N, 2014
  • Figure 7: 7MM, Diagnosed Prevalent Cases of SSc Classified as lSSc and dSSc, Both Sexes, Age ≥18 Years, N, 2014
Back to Top